ESTIMATED SAVINGS IN MEDICAL COSTS WHEN NEW ORAL ANTICOAGULANTS ARE USED FOR THE TREATMENT OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM VS. WARFARIN IN THE U.S

被引：1

作者：

Amin, A. ^{[1
]}

Bruno, A. ^{[2
]}

Trocio, J. ^{[3
]}

Lin, J. ^{[4
]}

Lingohr-Smith, M. ^{[4
]}

机构：

[1] Univ Calif Irvine, Irvine, CA USA

[2] Bristol Myers Squibb Co, Plainsboro, NJ USA

[3] Pfizer, New York, NY USA

[4] Novosys Hlth, Green Brook, NJ USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.802

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCV49

引用

页码：A138 / A138

页数：1

共 50 条

[21] Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Elfar, Sohil
Elzeiny, Sara Mohamed
Ismail, Hesham
Makkeyah, Yahya
Ibrahim, Mokhtar
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
[22] EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM. DATA FROM LJUBLJANA REGISTRY
Tratar, G.
Mavri, A.
THROMBOSIS RESEARCH, 2016, 141 : S4 - S4
[23] Comparative Use of Direct Oral Anticoagulants and Warfarin in the Treatment of Atrial Fibrillation and Venous Thromboembolism and Prophylaxis: A Retrospective Single Center Utilization Study
Hoang, Linda
Dela Cruz, Josephine Pineda
Farley, Stephen
Sessa, Julia
Chin, Jamie
Calixte, Rose
Hindenburg, Alexander
BLOOD, 2017, 130
[24] Should Newer Oral Anticoagulants Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism? New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation
Ansell, Jack
CIRCULATION, 2012, 125 (01) : 165 - 170
[25] Comparing Total Medical Costs between Patients Receiving Direct Oral Anticoagulants Versus Warfarin for the Treatment of Atrial Fibrillation: Evidence from the VA
Wong, E.
Done, N.
Zhao, M.
Woolley, A.
Prentice, J.
Mull, H.
HEALTH SERVICES RESEARCH, 2020, 55 : 79 - 80
[26] Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
Wang, Chun-Li
Huang, Chien-Hao
Wu, Victor Chien-Chia
Huang, Ya-Chi
Wang, Hsiang-Sheng
Kuo, Chang-Fu
Chu, Pao-Hsien
Wen, Ming-Shien
Chen, Ying-Jen
Huang, Yu-Tung
Chang, Shang-Hung
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[27] Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World
Hara, Nobuhiro
Lee, Tetsumin
Nozato, Toshihiro
Matsuyama, Mao Terui
Okata, Shinichiro
Nagase, Masashi
Mitsui, Kentaro
Nitta, Giichi
Watanabe, Keita
Miyazaki, Ryoichi
Nagamine, Sho
Kaneko, Masakazu
Nakamura, Tomofumi
Nagata, Yasutoshi
Miyamoto, Takamichi
Obayashi, Toru
Ashikaga, Takashi
CIRCULATION JOURNAL, 2022, 86 (06) : 923 - +
[28] Mixed Treatment Comparison Meta-Analysis of Aspirin, Warfarin, and New Anticoagulants for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
Assiri, Abdullah
Al-Majzoub, Omar
Kanaan, Abir O.
Donovan, Jennifer L.
Silva, Matthew
CLINICAL THERAPEUTICS, 2013, 35 (07) : 967 - 984
[29] Should Newer Oral Anticoagulants Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism? New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation Response
Granger, Christopher B.
Armaganijan, Luciana V.
CIRCULATION, 2012, 125 (01) : 170 - 170
[30] A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embolism
Turk, Murat
Aldag, Yagmur
Oguzulgen, Ipek Kivilcim
Ekim, Numan
TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2016, 64 (03): : 198 - 205

← 1 2 3 4 5 →